Top Markets
#1 GoPlus Security GoPlus Security +40.91%
#2 Tutorial Tutorial +21.27%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.85%
#4 Pons Pons +18.51%
#5 Status Status +14.44%
#6 SkyAI SkyAI +13.40%
#7 Verus Coin Verus Coin +13.11%
#8 Nillion Nillion +8.72%
#9 BankrCoin BankrCoin +8.66%
#10 Talus Network Talus Network +8.55%
Coin of the day
GoPlus Security GoPlus Security
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Vectus Biosystems Limited Vectus Biosystems Limited

Vectus Biosystems Limited

VBS
Rang in aandelen #33745
Vectus Biosystems Limited, an Australian medical research and development firm,... Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.
Aandeelprijs
$0.11637199
Marktkapitalisatie
$7.20M
Verandering (1 dag)
3.13%
Verandering (1 jaar)
171.06%
Land
AU
Handel Vectus Biosystems Limited (VBS)

Categorie

Healthcare
Winst voor Vectus Biosystems Limited (VBS)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Vectus Biosystems Limited bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Vectus Biosystems Limited van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE